We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App

COVID-19 Severity Test Reads Immune System in Real Time Using Machine Learning for Predicting Severe Outcomes

By LabMedica International staff writers
Posted on 28 Jul 2021
Print article
Image: MeMed COVID-19 Severity (Photo courtesy of MeMed)
Image: MeMed COVID-19 Severity (Photo courtesy of MeMed)
A new COVID-19 test reads the immune-system in real time to accurately determine whether SARS-Cov-2 patients are likely to have a severe outcome.

MeMed (Haifa, Israel) has received the CE Mark in Europe for its new disease management solution, MeMed COVID-19 Severity - a pioneering host response technology that measures multiple proteins from a serum sample and applies machine learning to stratify the risk that a patient with COVID-19 disease is likely to experience severe outcomes. The test runs in 15 minutes on the company’s point-of-need platform, MeMed Key, and aims to help physicians identify who may benefit from escalated care and who may be safely discharged from the hospital and instructed to self-isolate at home.

MeMed COVID-19 Severity is a predictive and actionable patient management tool. The test enables physicians to detect early the likelihood of deterioration in patients affected by COVID-19 and provides a leap forward in COVID-19 patient management. MeMed has recently published the results from a multinational derivation study, demonstrating the signature’s ability to accurately predict severe COVID-19 respiratory failure. The company has completed an additional independent multinational validation study; the results will be revealed in coming months.

“I am delighted that we are now able to commercialize a pioneering solution to help identify COVID-19 patients at risk of severe outcomes, empowering physicians to manage what is increasingly likely to become an endemic situation,” said Eran Eden, MeMed’s co-founder and CEO. “MeMed COVID-19 Severity is also relevant for authorities contemplating preparedness for future pandemics. It is another exciting step in the company’s long-term vision of harnessing the power of the host-immune response in order to transform the way infections are detected and managed.”

“Highly sensitive and accurate diagnostic and prognostic tests are key tools for clinicians,” said Sergey Motov, MD, Professor of Emergency Medicine, Maimonides Medical Center. “As an ER doctor myself, I am fascinated by the potential for host immune response technologies to help predict patient outcomes. Tools like MeMed COVID-19 Severity are a win-win solution: doctors can assess the likelihood of patients suffering from severe complications, enabling tailored treatments or discharge if the risk of deteriorating is low.”

Related Links:

Gold Supplier
Sample Transport
VACUETTE Transport Line
IFA Automated Processor
Silver Supplier
Automated Nucleic Acid Extractor
Silver Supplier
COVID-19 IgG-IgM Rapid Test
COVID-19 IgG-IgM Rapid Test

Print article



view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more


view channel

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.